Fulcrum Therapeutics Management
Management criteria checks 2/4
Fulcrum Therapeutics' CEO is Alex Sapir, appointed in Jul 2023, has a tenure of 1.42 years. total yearly compensation is $7.36M, comprised of 5% salary and 95% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth $926.19K. The average tenure of the management team and the board of directors is 2.1 years and 7.3 years respectively.
Key information
Alex Sapir
Chief executive officer
US$7.4m
Total compensation
| CEO salary percentage | 5.0% |
| CEO tenure | 1.4yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.1yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Dec 23
We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
Nov 08Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Sep 13Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Sep 12Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Jul 12Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Oct 28We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
Jul 11What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
Nov 17We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Oct 18Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts
Aug 13Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M
Aug 11Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave
Jul 11Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder
Jul 05Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling
Jun 27These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat
May 10Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth
Apr 09Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
Dec 09Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
Sep 03Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results
Aug 12News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts
Aug 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$20m |
| Mar 31 2024 | n/a | n/a | -US$99m |
| Dec 31 2023 | US$7m | US$369k | -US$97m |
Compensation vs Market: Alex's total compensation ($USD7.36M) is above average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Insufficient data to compare Alex's compensation with company performance.
CEO
Alex Sapir (57 yo)
1.4yrs
Tenure
US$7,360,015
Compensation
Mr. Alexander C. Sapir, also known as Alex, serves as Chief Executive Officer, President and Director at Fulcrum Therapeutics, Inc. since July 01, 2023. Mr. Sapir has been Director at PhaseBio Pharmaceutic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.4yrs | US$7.36m | 0.36% $ 926.2k | |
| Chief Financial Officer | 1.3yrs | US$2.15m | 0% $ 0 | |
| Senior VP | 4.1yrs | US$2.32m | 0.018% $ 46.5k | |
| Executive Vice President of Patient Experience | 1.2yrs | US$2.19m | 0.012% $ 32.0k | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Controller & Principal Accounting Officer | 2.8yrs | no data | 0.018% $ 47.6k | |
| Chief Scientific Officer | 2.1yrs | no data | no data | |
| Chief People Officer | 4.1yrs | no data | no data |
2.1yrs
Average Tenure
60.5yo
Average Age
Experienced Management: FULC's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 1.4yrs | US$7.36m | 0.36% $ 926.2k | |
| Independent Director | 8.4yrs | US$131.90k | 0.17% $ 434.5k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.9yrs | US$136.40k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 8.4yrs | US$724.50k | 0.93% $ 2.4m | |
| Independent Director | 8yrs | US$131.40k | 0.054% $ 138.6k | |
| Independent Chair of the Board | 6.5yrs | US$157.90k | 0% $ 0 | |
| Member of FSHD Clinical Advisory Board | no data | no data | no data | |
| Member of FSHD Clinical Advisory Board | no data | no data | no data | |
| Member of FSHD Clinical Advisory Board | no data | no data | no data | |
| Member of FSHD Clinical Advisory Board | no data | no data | no data |
7.3yrs
Average Tenure
67.5yo
Average Age
Experienced Board: FULC's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 11:06 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fulcrum Therapeutics, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |